Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends through 2018
- How will the future reimbursement changes affect individual market segment?
- Will the industry consolidate, decentralize, or undergo a bimodal transformation?
- What will be the impact on purchasing influences, marketing strategies, joint ventures, mergers, licensing, import and export?
- How will the future technological advances affect the major market segments?
- Which companies will enter the market and which will not survive?
This invaluable strategic planning resource is designed to help corporate, marketing and R&D executives develop effective business plans that best accommodate uncertainties ahead. The report evaluates emerging markets and technologies that may present unexpected threats or offer opportunities, identifies key strategic decisions that will have to be made in the future, and enhances corporate ability to develop realistic contingency plans.
The report presents strategic overview of the U.S. in vitro diagnostics market, including major regulatory, economic, demographic and social trends with potentially significant impact as well as five - and ten-year test volume and sales forecasts for major testing locations (hospitals, commercial labs, physician offices, blood centers, POC sites, and others) and laboratory disciplines (blood banking, clinical chemistry, immunodiagnostics, coagulation, hematology, flow cytometry, histology, cytology, microbiology, serology, urinalysis and others).
Contains 135 pages and 11 tables
1. EXECUTIVE SUMMARY
2. CONCLUSIONS AND RECOMMENDATIONS
3. BUSINESS ENVIRONMENT
a. Health Care Expenditures
b. Cost-Consciousness
c. Reimbursement
d. Industry Consolidation
e. Hospitals
f. Admissions
g. Length of Stay
h. Industry Diversification
i. Physician Demographics
j. Aging Population
More Chronic Illnesses
Higher Incidence of Disease
Greater Susceptibility to Iatrogenesis
More Cases with Multiple Illnesses
4. OUTLOOK FOR THE IN VITRO DIAGNOSTICS MARKET
a. Government Regulations
b. FDA Reform
c. Hospitals
d. Commercial Laboratories
e. Physician Offices
f. Point-of-Care Testing
g. Personal Testing
h. Other Testing Locations
5. STRATEGIC IMPLICATIONS
a. Testing Patterns
Test Utilization
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
6. MARKET SEGMENTS
a. Clinical Chemistry and Immunodiagnostics
Introduction
Future Situation
b. Microbiology and Serology
Introduction
Future Situation
c. Hematology and Flow Cytometry
Introduction
Future Situation
d. Blood Banking
Introduction
Future Situation
e. Histology and Cytology
Introduction
Future Situation
f. Coagulation
Introduction
Future Situation
g. Urinalysis
Introduction
Future Situation
7. TECHNOLOGIES
a. Molecular Diagnostics
Introduction
Future Situation
b. Monoclonal Antibodies
Introduction
Future Situation
c. Solid Phase Chemistry
Introduction
Future Situation
d. Biosensors and Biochips
Introduction
Future Situation
e. Automation and Robotics
Introduction
Future Situation
f. IT
Introduction
Future Situation
8. THE NEW MARKETPLACE
a. Purchasing Influences
b. Marketing Strategies
c. Joint Venture, Merger, and Licensing Activity
d. Import-Export
e. Potential Market Entrants
f. Who May Not Survive?
2. CONCLUSIONS AND RECOMMENDATIONS
3. BUSINESS ENVIRONMENT
a. Health Care Expenditures
b. Cost-Consciousness
c. Reimbursement
d. Industry Consolidation
e. Hospitals
f. Admissions
g. Length of Stay
h. Industry Diversification
i. Physician Demographics
j. Aging Population
More Chronic Illnesses
Higher Incidence of Disease
Greater Susceptibility to Iatrogenesis
More Cases with Multiple Illnesses
4. OUTLOOK FOR THE IN VITRO DIAGNOSTICS MARKET
a. Government Regulations
b. FDA Reform
c. Hospitals
d. Commercial Laboratories
e. Physician Offices
f. Point-of-Care Testing
g. Personal Testing
h. Other Testing Locations
5. STRATEGIC IMPLICATIONS
a. Testing Patterns
Test Utilization
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
6. MARKET SEGMENTS
a. Clinical Chemistry and Immunodiagnostics
Introduction
Future Situation
b. Microbiology and Serology
Introduction
Future Situation
c. Hematology and Flow Cytometry
Introduction
Future Situation
d. Blood Banking
Introduction
Future Situation
e. Histology and Cytology
Introduction
Future Situation
f. Coagulation
Introduction
Future Situation
g. Urinalysis
Introduction
Future Situation
7. TECHNOLOGIES
a. Molecular Diagnostics
Introduction
Future Situation
b. Monoclonal Antibodies
Introduction
Future Situation
c. Solid Phase Chemistry
Introduction
Future Situation
d. Biosensors and Biochips
Introduction
Future Situation
e. Automation and Robotics
Introduction
Future Situation
f. IT
Introduction
Future Situation
8. THE NEW MARKETPLACE
a. Purchasing Influences
b. Marketing Strategies
c. Joint Venture, Merger, and Licensing Activity
d. Import-Export
e. Potential Market Entrants
f. Who May Not Survive?
LIST OF TABLES
Executive Summary Table: Growth Areas in Clinical Laboratory Testing
Table-1: Estimated U.S. Health Care Expenditures By Expenditure Type
Table-2: Health Plan Enrollment Distribution
Table-3: Selected Hospital Statistics
Table-4: Total Population And Physician Demographics
Table-5: Test Volume By Location
Table-6: Test Distribution By Location
Table-7: Market Size By Location
Table-8: Typical Pre-Admission Tests
Table-9: Test Volume By Laboratory Discipline
Table-10: Market Size By Laboratory Discipline
Executive Summary Table: Growth Areas in Clinical Laboratory Testing
Table-1: Estimated U.S. Health Care Expenditures By Expenditure Type
Table-2: Health Plan Enrollment Distribution
Table-3: Selected Hospital Statistics
Table-4: Total Population And Physician Demographics
Table-5: Test Volume By Location
Table-6: Test Distribution By Location
Table-7: Market Size By Location
Table-8: Typical Pre-Admission Tests
Table-9: Test Volume By Laboratory Discipline
Table-10: Market Size By Laboratory Discipline
